Intercept Pharmaceuticals (ICPT) gains on trial data

March 20, 2015 10:39 AM | 10 seconds read | Make a Comment

Intercept Pharmaceuticals, Inc.

ICPT

shares rose 2.3% to $295.05 on positive Phase 2b Flint trial data. Share volume was 438,000, compared to an all-day average of 578,000

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.